Genable Technologies Ltd.

About:

Genable Technologies Ltd. is a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company developing new gene

Website: http://www.genable.net

Top Investors: Fountain Healthcare Partners

Description:

Genable Technologies Ltd. is a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company developing new gene medicines to treat "dominant" genetic diseases based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries. Genable utilizes well-established, clinically safe & effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein. The combination of suppression and replacement (S&R) overcomes the significant hurdle in dominant disease of mutation variability by eliminating the need to target specific mutations in a wide range of disorders. Genable's technology is protected by a broad suite of granted patents and patent applications in the USA, EU and worldwide.

Total Funding Amount:

5M EUR

Headquarters Location:

Dublin, Dublin, Ireland

Founded Date:

2001-01-01

Contact Email:

jloveridge(AT)genable.net

Founders:

Jane Farrar, Paul Kenna

Number of Employees:

1-10

Last Funding Date:

2009-11-10

IPO Status:

Private

Industries:

© 2025 bioDAO.ai